{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T21:27:12Z","timestamp":1781299632192,"version":"3.54.1"},"reference-count":22,"publisher":"International Heart Journal (Japanese Heart Journal)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int. Heart J."],"published-print":{"date-parts":[[2024,3,30]]},"DOI":"10.1536\/ihj.23-563","type":"journal-article","created":{"date-parts":[[2024,3,29]],"date-time":"2024-03-29T22:18:07Z","timestamp":1711750687000},"page":"211-217","source":"Crossref","is-referenced-by-count":6,"title":["Efficacy and Tolerability of Ivabradine for Cardiomyopathy in Patients with Duchenne Muscular Dystrophy"],"prefix":"10.1536","volume":"65","author":[{"given":"Akiko","family":"Wakisaka","sequence":"first","affiliation":[{"name":"Department of Pediatrics, NHO Iou National Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Kimura","sequence":"additional","affiliation":[{"name":"Departments of Laboratory Medicine and Cardiology, The Institute of Medical Science, The University of Tokyo"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Morita","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Graduate School of Medicine, The University of Tokyo"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koki","family":"Nakanishi","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Graduate School of Medicine, The University of Tokyo"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masao","family":"Daimon","sequence":"additional","affiliation":[{"name":"Department of Cardiology, International University of Health and Welfare Mita Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanori","family":"Nojima","sequence":"additional","affiliation":[{"name":"Center for Translational Research, The Institute of Medical Science, The University of Tokyo"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Itoh","sequence":"additional","affiliation":[{"name":"Division of Patient Safety, Hiroshima University Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsuhito","family":"Takeda","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Hokkaido University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruriko","family":"Kitao","sequence":"additional","affiliation":[{"name":"Department of Neurology, NHO Hakone Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomihiro","family":"Imai","sequence":"additional","affiliation":[{"name":"Department of Neurology, NHO Hakone Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuhiko","family":"Ikeda","sequence":"additional","affiliation":[{"name":"Department of Neurology, NHO Niigata National Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Nakajima","sequence":"additional","affiliation":[{"name":"Department of Neurology, NHO Niigata National Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chigusa","family":"Watanabe","sequence":"additional","affiliation":[{"name":"Department of Neurology, NHO Hiroshimanishi Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshihiro","family":"Furukawa","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, NHO Hiroshimanishi Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ichiro","family":"Ohno","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, NHO Iou National Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiho","family":"Ishida","sequence":"additional","affiliation":[{"name":"Department of Neurology, NHO Iou National Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norihiko","family":"Takeda","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Graduate School of Medicine, The University of Tokyo"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiyonobu","family":"Komai","sequence":"additional","affiliation":[{"name":"Department of Neurology, NHO Iou National Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"437","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Matthews E, Brassington R, Kuntzer T, Jichi F, Manzur AY. Corticosteroids for the treatment of Duchenne muscular dystrophy. Cochrane Database Syst Rev 2016; 2016: Cd003725.","DOI":"10.1002\/14651858.CD003725.pub4"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Yusuf S, Pitt B, Davis CE, Hood WB, Cohn JN. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325: 293-302.","DOI":"10.1056\/NEJM199108013250501"},{"key":"3","doi-asserted-by":"publisher","unstructured":"3. Bourke JP, Watson G, Muntoni F, <i>et al<\/i>. Randomised placebo-controlled trial of combination ACE inhibitor and beta-blocker therapy to prevent cardiomyopathy in children with Duchenne muscular dystrophy? (DMD Heart Protection Study): a protocol study. BMJ Open 2018; 8: e022572.","DOI":"10.1136\/bmjopen-2018-022572"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Rhodes J, Margossian R, Darras BT, <i>et al<\/i>. Safety and efficacy of carvedilol therapy for patients with dilated cardiomyopathy secondary to muscular dystrophy. Pediatr Cardiol 2008; 29: 343-51.","DOI":"10.1007\/s00246-007-9113-z"},{"key":"5","doi-asserted-by":"publisher","unstructured":"5. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 1999; 353: 9-13.","DOI":"10.1016\/S0140-6736(98)11181-9"},{"key":"6","doi-asserted-by":"publisher","unstructured":"6. Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease. Australia\/New Zealand Heart Failure Research Collaborative Group. Lancet 1997; 349: 375-80.","DOI":"10.1016\/S0140-6736(97)80008-6"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Kieny P, Chollet S, Delalande P, <i>et al<\/i>. Evolution of life expectancy of patients with Duchenne muscular dystrophy at AFM Yolaine de Kepper centre between 1981 and 2011. Ann Phys Rehabil Med 2013; 56: 443-54.","DOI":"10.1016\/j.rehab.2013.06.002"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Seguchi O, Kuroda K, Fujita T, <i>et al<\/i>. Heart Transplantation Ameliorates Ambulation Capacity in Patients With Muscular Dystrophy - An Analysis of 9 Cases. Circ J 2019; 83: 684-6.","DOI":"10.1253\/circj.CJ-18-1060"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Sabharwal R. The link between stress disorders and autonomic dysfunction in muscular dystrophy. Front Physiol 2014; 5: 25.","DOI":"10.3389\/fphys.2014.00025"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Sabharwal R. Autonomic regulation in muscular dystrophy. Front Physiol 2014; 5: 61.","DOI":"10.3389\/fphys.2014.00061"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Thomas TO, Jefferies JL, Lorts A, <i>et al<\/i>. Autonomic dysfunction: a driving force for myocardial fibrosis in young Duchenne muscular dystrophy patients? Pediatr Cardiol 2015; 36: 561-8.","DOI":"10.1007\/s00246-014-1050-z"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Kimura K, Takenaka K, Ebihara A, <i>et al<\/i>. Prognostic impact of left ventricular noncompaction in patients with Duchenne\/Becker muscular dystrophy--prospective multicenter cohort study. Int J Cardiol 2013; 168: 1900-4.","DOI":"10.1016\/j.ijcard.2012.12.058"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Kimura K, Morita H, Daimon M, <i>et al<\/i>. Prognostic impact of venous thromboembolism in patients with Duchenne muscular dystrophy: Prospective multicenter 5-year cohort study. Int J Cardiol 2015; 191: 178-80.","DOI":"10.1016\/j.ijcard.2015.04.244"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Hor KN, Taylor MD, Al-Khalidi HR, <i>et al<\/i>. Prevalence and distribution of late gadolinium enhancement in a large population of patients with Duchenne muscular dystrophy: effect of age and left ventricular systolic function. J Cardiovasc Magn Reson 2013; 15: 107.","DOI":"10.1186\/1532-429X-15-107"},{"key":"15","doi-asserted-by":"publisher","unstructured":"15. Swedberg K, Komajda M, B\u00f6hm M, <i>et al<\/i>. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet 2010; 376: 875-85.","DOI":"10.1016\/S0140-6736(10)61198-1"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Geng X, Zhang J, Zhang Y, Hu H, Yang J, Cui W. Revisiting the clinical evidence of heart rate target in patients with heart failure treated with beta-blockers. Anatol J Cardiol 2021; 25: 762-73.","DOI":"10.5152\/AnatolJCardiol.2021.90"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Tsutsui H, Momomura SI, Yamashina A, <i>et al<\/i>. Efficacy and Safety of Ivabradine in Japanese Patients With Chronic Heart Failure - J-SHIFT Study. Circ J 2019; 83: 2049-60.","DOI":"10.1253\/circj.CJ-19-0227"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Adorisio R, Calvieri C, Cantarutti N, <i>et al<\/i>. Heart rate reduction strategy using ivabradine in end-stage Duchenne cardiomyopathy. Int J Cardiol 2019; 280: 99-103.","DOI":"10.1016\/j.ijcard.2019.01.052"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. De Benedittis G, Della Rosa G, D&apos;Ettorre E, Piscitelli P, Distante A, de Gregorio C. Effect of Ivabradine in dilated cardiomyopathy from Duchenne muscular dystrophy: A chance for slowing progression of heart failure? Int J Cardiol 2016; 223: 286-8.","DOI":"10.1016\/j.ijcard.2016.08.135"},{"key":"20","doi-asserted-by":"publisher","unstructured":"20. B\u00f6hm M, Swedberg K, Komajda M, <i>et al<\/i>. Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial. Lancet 2010; 376: 886-94.","DOI":"10.1016\/S0140-6736(10)61259-7"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Schade van Westrum S, Dekker L, de Haan R, <i>et al<\/i>. Brain natriuretic peptide is not predictive of dilated cardiomyopathy in Becker and Duchenne muscular dystrophy patients and carriers. BMC Neurol 2013; 13: 88.","DOI":"10.1186\/1471-2377-13-88"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Kawakubo M, Funabashi N, Takahashi M, <i>et al<\/i>. Relationship of natriuretic peptide and transthoracic echocardiographic findings in 135 subjects with muscular dystrophy. Int J Cardiol 2010; 145: 506-14.","DOI":"10.1016\/j.ijcard.2009.12.018"}],"container-title":["International Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ihj\/65\/2\/65_23-563\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,30]],"date-time":"2024-03-30T04:45:18Z","timestamp":1711773918000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ihj\/65\/2\/65_23-563\/_article"}},"subtitle":["One Year Treatment Results in Japanese National Hospitals"],"short-title":[],"issued":{"date-parts":[[2024,3,30]]},"references-count":22,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1536\/ihj.23-563","relation":{},"ISSN":["1349-2365","1349-3299"],"issn-type":[{"value":"1349-2365","type":"print"},{"value":"1349-3299","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,30]]},"article-number":"23-563"}}